Published in Proc Natl Acad Sci U S A on August 15, 1993
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol (1994) 3.45
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol (1995) 3.05
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A (1994) 2.59
In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol (1996) 2.22
Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother (1995) 2.21
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother (1996) 2.13
Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol (1995) 2.05
Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci U S A (1996) 1.93
Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol (1994) 1.80
Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol (1995) 1.80
Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J Virol (1995) 1.78
Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev (1995) 1.49
Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol (1998) 1.38
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother (2006) 1.37
Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother (1998) 1.29
HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog (2014) 1.25
Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol (1995) 1.23
A preference-based free-energy parameterization of enzyme-inhibitor binding. Applications to HIV-1-protease inhibitor design. Protein Sci (1995) 1.21
Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1998) 1.21
Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor. J Clin Microbiol (1999) 1.12
Structure of equine infectious anemia virus proteinase complexed with an inhibitor. Protein Sci (1996) 1.00
A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. J Virol (1997) 0.95
Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob Agents Chemother (2002) 0.95
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob Agents Chemother (2005) 0.94
Use of tissue culture cell lines to evaluate HIV antiviral resistance. AIDS Res Hum Retroviruses (2008) 0.93
Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection. Antimicrob Agents Chemother (1996) 0.93
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol (2000) 0.88
In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomes. PLoS One (2012) 0.81
Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine. Antimicrob Agents Chemother (1996) 0.80
Prototypical Recombinant Multi-Protease Inhibitor Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type-1. Antimicrob Agents Chemother (2013) 0.80
Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine. Antimicrob Agents Chemother (1996) 0.79
The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy. Gene Ther (2015) 0.79
Solvation effects are responsible for the reduced inhibitor affinity of some HIV-1 PR mutants. Protein Sci (1997) 0.75
Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen. AIDS Res Ther (2005) 0.75
On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun (1967) 18.32
Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A (1988) 10.77
Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol (1991) 7.01
Complete mutagenesis of the HIV-1 protease. Nature (1989) 5.16
Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 4.57
Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol (1991) 3.33
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science (1990) 2.83
A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science (1990) 2.80
Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses (1989) 2.62
In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol Pharmacol (1992) 2.55
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1991) 2.16
HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem Biophys Res Commun (1988) 2.14
Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease. Cell (1988) 2.01
Structure-based, C2 symmetric inhibitors of HIV protease. J Med Chem (1990) 1.72
Accurate prediction of the stability and activity effects of site-directed mutagenesis on a protein core. Nature (1991) 1.65
Cooperative dimeric and tetrameric clam haemoglobins are novel assemblages of myoglobin folds. Nature (1985) 1.62
Peptide substrates and inhibitors of the HIV-1 protease. Biochem Biophys Res Commun (1989) 1.52
Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc Natl Acad Sci U S A (1989) 1.47
Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer. Proc Natl Acad Sci U S A (1990) 1.40
High-level synthesis of recombinant HIV-1 protease and the recovery of active enzyme from inclusion bodies. Gene (1990) 1.33
Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins (1991) 1.29
Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J Biol Chem (1990) 1.29
Computational method for the design of enzymes with altered substrate specificity. J Mol Biol (1991) 1.24
Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. J Biol Chem (1992) 1.20
PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains. Virology (1992) 1.13
Affinity purification of HIV-1 and HIV-2 proteases from recombinant E. coli strains using pepstatin-agarose. Biochem Biophys Res Commun (1990) 1.04
L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. J Med Chem (1991) 1.00
Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes. J Med Chem (1991) 0.89
Selective phosphinate transition-state analogue inhibitors of the protease of human immunodeficiency virus. Biochem Biophys Res Commun (1990) 0.87
Interaction of mutant forms of the HIV-1 protease with substrate and inhibitors. Adv Exp Med Biol (1991) 0.81
Molecular characterization of HIV-2 (ROD) protease following PCR cloning from virus infected H9 cells. Adv Exp Med Biol (1992) 0.81
Transcriptional induction of two genes in human cells by beta interferon. Proc Natl Acad Sci U S A (1984) 4.84
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science (1994) 3.44
Human cytomegalovirus tegument protein pp71 (ppUL82) enhances the infectivity of viral DNA and accelerates the infectious cycle. J Virol (1997) 3.16
Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. J Cell Physiol (1995) 2.80
Brevetoxin concentrations in marine aerosol: human exposure levels during a Karenia brevis harmful algal bloom. Bull Environ Contam Toxicol (2003) 2.53
Flexibility and function in HIV-1 protease. Nat Struct Biol (1995) 2.49
Interactions of alpha- and gamma-interferon in the transcriptional regulation of the gene encoding a guanylate-binding protein. EMBO J (1989) 2.39
Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology (1995) 2.29
Detection of phosphotyrosine-containing 34,000-dalton protein in the framework of cells transformed with Rous sarcoma virus. Proc Natl Acad Sci U S A (1981) 2.09
Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol (1999) 2.01
Self-assembly and calcium-binding sites in laminin. A three-arm interaction model. J Biol Chem (1993) 2.01
Interferon induction of fibroblast proteins with guanylate binding activity. J Biol Chem (1983) 1.87
Alterations of spore coat processing and protein turnover in a Bacillus cereus mutant with a defective postexponential intracellular protease. Proc Natl Acad Sci U S A (1977) 1.86
Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. J Pediatr (1996) 1.84
Laminin forms an independent network in basement membranes. J Cell Biol (1992) 1.68
Crystal structure of scytalone dehydratase--a disease determinant of the rice pathogen, Magnaporthe grisea. Structure (1994) 1.59
Stabilization of a degradable protein by its overexpression in Escherichia coli. Gene (1981) 1.48
Biodegradable rapamycin-eluting nano-fiber membrane-covered metal stent placement to reduce fibroblast proliferation in experimental stricture in a canine model. Endoscopy (2013) 1.48
Interferon-induced guanylate-binding proteins lack an N(T)KXD consensus motif and bind GMP in addition to GDP and GTP. Mol Cell Biol (1991) 1.47
Purification and characterization of protease III from Escherichia coli. J Biol Chem (1979) 1.46
Peripheral symmetrical gangrene successfully treated with epoprostenol and tissue plasminogen activator. Lancet (1986) 1.44
Nominal shear or fracture mechanics in the assessment of composite-dentin adhesion? J Dent Res (2000) 1.44
Isolation and characterization of mutations in the structural gene for protease III (ptr). J Bacteriol (1979) 1.44
A comparison of the use of polythene sheet and Jelonet as temporary dressings for excised wounds. Br J Plast Surg (1992) 1.39
Measles virus spread between neurons requires cell contact but not CD46 expression, syncytium formation, or extracellular virus production. J Virol (2000) 1.35
Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS (1996) 1.34
Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med (1986) 1.33
Heterogeneity of Streptococcus mutans strains based on their mannitol-1-phosphate dehydrogenases: criterion for rapid classification. Infect Immun (1972) 1.29
Rhodococcus equi infection in the patient with AIDS: literature review and report of an unusual case. Rev Infect Dis (1991) 1.29
Ethanol production and alcohol dehydrogenase activity in Streptococcus mutans. Arch Oral Biol (1973) 1.26
Regulation of endothelial cell myosin light chain kinase by Rho, cortactin, and p60(src). Am J Physiol (1999) 1.26
Plastic surgery audit codes: are the results reproducible? Br J Plast Surg (1991) 1.25
Reducing time limits: a means to increase behavior of retardates. J Appl Behav Anal (1976) 1.24
Automated construction of high-density comparative maps between rat, human, and mouse. Genome Res (2001) 1.24
Elemental analysis of freeze-dried thin sections of Samanea motor organs: barriers to ion diffusion through the apoplast. J Cell Biol (1982) 1.24
Affinity purification of an interferon-induced human guanylate-binding protein and its characterization. J Biol Chem (1985) 1.23
Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas. J Med Chem (1996) 1.20
Characterization and chemical properties of phosphoribosylamine, an unstable intermediate in the de novo purine biosynthetic pathway. Biochemistry (1988) 1.20
Mapping of network-forming, heparin-binding, and alpha 1 beta 1 integrin-recognition sites within the alpha-chain short arm of laminin-1. J Biol Chem (1995) 1.18
Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry (1997) 1.18
Characterization of a phosphotyrosyl protein phosphatase activity associated with a phosphoseryl protein phosphatase of Mr = 95,000 from bovine heart. J Biol Chem (1983) 1.18
Expression of keratin and vimentin intermediate filaments in rabbit bladder epithelial cells at different stages of benzo[a]pyrene-induced neoplastic progression. J Cell Biol (1981) 1.16
Wound infection and septic shock due to Vibrio vulnificus. Am J Trop Med Hyg (1981) 1.13
Plasmid DNA fingerprinting of Acinetobacter calcoaceticus subspecies anitratus from intubated and mechanically ventilated patients. Infect Control Hosp Epidemiol (1990) 1.12
Intraosseous oral leiomyoma: systematic review and report of one case. Dentomaxillofac Radiol (2003) 1.11
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues. J Med Chem (1998) 1.09
Expression of a novel high molecular-weight myosin light chain kinase in endothelium. Am J Respir Cell Mol Biol (1998) 1.09
Nonidentical induction of the guanylate binding protein and the 56K protein by type I and type II interferons. J Interferon Res (1986) 1.09
Erythroid colony growth in vitro from human peripheral blood null cells: evidence for regulation by T-lymphocytes and monocytes. Br J Haematol (1981) 1.08
Regulation of endothelial cell gap formation and barrier function by myosin-associated phosphatase activities. Am J Physiol (1995) 1.08
Bacterial induction of pleural mesothelial monolayer barrier dysfunction. Am J Physiol Lung Cell Mol Physiol (2001) 1.07
Biochemical regulation of the nonmuscle myosin light chain kinase isoform in bovine endothelium. Am J Respir Cell Mol Biol (1998) 1.07
Diperoxovanadate alters endothelial cell focal contacts and barrier function: role of tyrosine phosphorylation. J Appl Physiol (1985) (2000) 1.07
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol (1996) 1.06
Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease. Protein Sci (1999) 1.05
Protein interactions of Src homology 2 (SH2) domain-containing inositol phosphatase (SHIP): association with Shc displaces SHIP from FcgammaRIIb in B cells. J Immunol (1999) 1.05
Scurvy: MRI appearances. Rheumatology (Oxford) (2008) 1.04
Delayed bactericidal activity of beta-lactam antibiotics against Listeria monocytogenes: antagonism of chloramphenicol and rifampin. Antimicrob Agents Chemother (1983) 1.04
Infant mortality and early postpartum discharge. Obstet Gynecol (2000) 1.04
Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. Biochemistry (1998) 1.03
Measurements of airway dimensions and calculation of mass transfer characteristics of the human oral passage. J Biomech Eng (1997) 1.02
Characterization of a Bacillus cereus protease mutant defective in an early stage of spore germination. J Bacteriol (1978) 1.02
Vascular endothelial cell activation and permeability responses to thrombin. Blood Coagul Fibrinolysis (1995) 1.02
The vascular territory of the acromiothoracic axis. Br J Plast Surg (1984) 1.01
In vitro activities of trimethoprim and sulfamethoxazole against Listeria monocytogenes. Antimicrob Agents Chemother (1982) 1.01
Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors. Antiviral Res (1995) 1.01
Characterization and function of intracellular proteases in sporulating Bacillus cereus. Arch Microbiol (1977) 1.01
Endometrial extramedullary haemopoiesis. J Pathol (1995) 1.01
Evaluation of MR spectroscopy and diffusion-weighted MRI in detecting bone marrow changes in postmenopausal women with osteoporosis. Clin Radiol (2010) 1.00
Different mRNAs induced by interferon in cells from inbred mouse strains A/J and A2G. J Virol (1983) 1.00
In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrob Agents Chemother (1993) 1.00
Molecular recognition of cyclic urea HIV-1 protease inhibitors. J Biol Chem (1998) 1.00
Mechanisms of ionomycin-induced endothelial cell barrier dysfunction. Am J Physiol (1997) 0.99
Juvenile xanthogranuloma variant: a clinicopathological case report and review of the literature. Br J Plast Surg (1999) 0.98
Prognosis of uterine cervical cancer with extensive lymph node metastases. Special emphasis on the value of pelvic lymphadenectomy in the surgical treatment of uterine cervical cancer. Am J Obstet Gynecol (1972) 0.98
Thrombin-mediated focal adhesion plaque reorganization in endothelium: role of protein phosphorylation. Am J Respir Cell Mol Biol (1997) 0.97
Self-assembly of a high molecular weight basement membrane heparan sulfate proteoglycan into dimers and oligomers. J Biol Chem (1987) 0.96
Protein kinase C phosphorylates caldesmon77 and vimentin and enhances albumin permeability across cultured bovine pulmonary artery endothelial cell monolayers. J Cell Physiol (1992) 0.96
Pulmonary toxicity of inhaled diesel exhaust and carbon black in chronically exposed rats. Part I: Neoplastic and nonneoplastic lung lesions. Res Rep Health Eff Inst (1994) 0.96
Increased cell buoyant densities of protein overproducing Escherichia coli cells. Biochem Biophys Res Commun (1983) 0.94
Neonatal lipopolysaccharide exposure delays puberty and alters hypothalamic Kiss1 and Kiss1r mRNA expression in the female rat. J Neuroendocrinol (2009) 0.93
The mechanism of the anaemia in rheumatoid arthritis: effects of bone marrow adherent cells and of serum on in-vitro erythropoiesis. Br J Haematol (1984) 0.93
In vitro activity of silicon carbide whiskers in comparison to other industrial fibers using four cell culture systems. Am J Ind Med (1992) 0.92
Fracture toughness of conventional, resin-modified glass-ionomer and composite luting cements. Dent Mater (1999) 0.91
Effectiveness of mattress overlays in reducing interface pressures during recumbency. J Rehabil Res Dev (1985) 0.91
Fitting an inhibitor into the active site of thermolysin: a molecular dynamics case study. Proteins (1996) 0.91
Heparin modulation of laminin polymerization. J Biol Chem (1990) 0.90
Genetic parameters of reproductive traits in Brown Tsaiya ducks artificially inseminated with semen from Muscovy drakes. Poult Sci (2001) 0.90
Preliminary crystallographic studies on scytalone dehydratase from Magnaporthe grisea. J Mol Biol (1993) 0.90